Impact of a value-based formulary in three chronic disease cohorts

The American journal of managed care

Volumn 23, Issue 3, 2017, Pages S46-S53

  Yeung, Kai ^a   Basu, Anirban ^b   Marcum, Zachary A ^b   Watkins, John B ^b   Sullivan, Sean D ^b  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CASE CONTROL STUDY; DIABETES MELLITUS; ECONOMICS; EPIDEMIOLOGY; FEE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PUBLICATION; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEES, PHARMACEUTICAL; FEMALE; FORMULARIES AS TOPIC; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSURANCE, PHARMACEUTICAL SERVICES; INTERRUPTED TIME SERIES ANALYSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; UNITED STATES;

EID: 85029864111     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Article

References (0)